AURA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AURA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Aura Biosciences's quarterly cash and cash equivalents declined from Sep. 2023 ($55.58 Mil) to Dec. 2023 ($41.06 Mil) but then stayed the same from Dec. 2023 ($41.06 Mil) to Mar. 2024 ($26.28 Mil).
Aura Biosciences's annual cash and cash equivalents declined from Dec. 2021 ($149.06 Mil) to Dec. 2022 ($121.58 Mil) and declined from Dec. 2022 ($121.58 Mil) to Dec. 2023 ($41.06 Mil).
The historical data trend for Aura Biosciences's Cash And Cash Equivalents can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aura Biosciences Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Cash And Cash Equivalents | 32.45 | 17.39 | 149.06 | 121.58 | 41.06 |
Aura Biosciences Quarterly Data | |||||||||||||||||
Dec19 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cash And Cash Equivalents | Get a 7-Day Free Trial | 38.49 | 47.73 | 55.58 | 41.06 | 26.28 |
Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.
Aura Biosciences (NAS:AURA) Cash And Cash Equivalents Explanation
A high number means either:
1) The company has competitive advantage generating lots of cash
2) Just sold a business or bonds (not necessarily good)
A low stockpile of cash usually means poor to mediocre economics.
There are 3 ways to create large cash reserve.
1) Sell new bonds or equity to public
2) Sell business or asset
3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)
When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.
Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.
Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.
Be Aware
Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.
Thank you for viewing the detailed overview of Aura Biosciences's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.
Matrix Capital Management Company, Lp | 10 percent owner | 1000 WINTER STREET, C/O MATRIX CAPITAL MANAGEMENT, WALTHAM MA 02451 |
David Michael Johnson | director | C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018 |
Julie B Feder | officer: Chief Financial Officer | C/O VERASTEM, INC., 117 KENDRICK STREET, SUITE 500, NEEDHAM MA 02494 |
De Los Pinos Elisabet | director, officer: Chief Executive Officer | C/O AURA BIOSCIENCES, INC., 85 BOLTON STREET, CAMBRIDGE MA 02140 |
Janet Jill Hopkins | officer: See Remarks | C/O AURA BIOSCIENCES, INC., 80 GUEST STREET, BOSTON MA 01235 |
Cadmus Rich | officer: See Remarks | C/O AURA BIOSCIENCES, INC., 85 BOLTON STREET, CAMBRIDGE MA 02140 |
Rosch Mark De | officer: Chief Operating Officer | C/O AURA BIOSCIENCES, INC., 85 BOLTON STREET, CAMBRIDGE MA 02140 |
Medicxi Ventures Management (jersey) Ltd | 10 percent owner | C/O INTERTRUST FUND SERVICES (JERSEY), 44 ESPLANADE, ST. HELIER Y9 JE4 9WG |
Medicxi Growth I Lp | 10 percent owner | C/O ELIAN FUND SERVICES (JERSEY) LIMITED, 44 ESPLANADE, ST HELIER Y9 JE4 9WG |
Giovanni Mariggi | director | C/O AURA BIOSCIENCES, INC., 85 BOLTON STREET, CAMBRIDGE MA 02140 |
Medicxi Growth I Gp Ltd | 10 percent owner | C/O INTERTRUST FUND SERVICES (JERSEY), 44 ESPLANADE, ST. HELIER Y9 JE4 9WG |
Medicxi Growth Co-invest I Lp | 10 percent owner | C/O INTERTRUST FUND SERVICES (JERSEY), 44 ESPLANADE, ST. HELIER Y9 JE4 9WG |
David E. Goel | 10 percent owner | C/O MATRIX CAPITAL MANAGEMENT CO., LP, 1000 WINTER STREET, SUITE 4500, WALTHAM MA 02451 |
Karan S. Takhar | director | C/O ZENTALIS PHARMACEUTICALS,INC., 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018 |
Antony C. Mattessich | director | C/O OCULAR THERAPEUTIX, INC., 34 CROSBY DR., SUITE 105, BEDFORD MA 01730 |
From GuruFocus
By Business Wire Business Wire • 03-21-2022
By Business Wire Business Wire • 05-03-2022
By Business Wire • 11-07-2023
By Business Wire • 11-06-2023
By Business Wire Business Wire • 05-26-2022
By Business Wire Business Wire • 02-28-2022
By Business Wire Business Wire • 05-03-2022
By Business Wire Business Wire • 05-24-2023
By Business Wire Business Wire • 02-16-2023
By Business Wire Business Wire • 02-14-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.